Ibogaine and 5-MeO-DMT are used together in ceremony for PTSD, depression, and addiction — not as alternatives to each other, but because they address different layers of the same conditions. Ibogaine produces 12–24 hours of specific autobiographical content: a direct encounter with the structure of a person's life. 5-MeO-DMT produces 20–45 minutes of ego dissolution with no narrative content at all. For some people, the second completes what the first starts.
Ibogaine and 5-MeO-DMT work through different mechanisms and address different layers of the same conditions. Ibogaine operates through narrative — biographical memory review over 12–24 hours. 5-MeO-DMT operates through dissolution — temporary removal of the self-structure that organises suffering. Neither is a lighter version of the other. They are complementary, not interchangeable.
What Ibogaine Produces
Ibogaine acts on multiple receptor systems simultaneously — dopamine, opioid, NMDA, and sigma-2 receptors — producing a 12–24 hour experience characterised by extended autobiographical memory review. This is not hallucination in the conventional sense. It is a specific and often confrontational encounter with the events, relationships, and patterns that have shaped a person's life. The medicine tends to route toward what has been avoided rather than toward what the person came hoping to find.
The 2023 Stanford study, published in Nature Medicine, documented what practitioners had been observing for years. Thirty special operations veterans with treatment-resistant PTSD, depression, and traumatic brain injury received a single ibogaine session. At one month post-treatment: PTSD symptoms decreased by an average of 88%, depression by 87%, anxiety by 81%. For context, conventional antidepressant research considers a 50% reduction in depression scores a strong response.
Ibogaine also triggers the release of GDNF and BDNF — glial cell-line derived neurotrophic factor and brain-derived neurotrophic factor — which drive neuroplastic changes that persist for weeks to months after ceremony. Noribogaine, ibogaine's active metabolite, remains biologically active long after the acute experience ends, sustaining elevated serotonin transporter modulation and continuing to influence mood and craving. This is the neuroplasticity window — the period when integration does its most consequential work.
What ibogaine does not produce is dissolution of the self. The narrative stays intact throughout. The person doing the reviewing is still present — observing, encountering, confronting — but they remain themselves. This is the primary distinction from 5-MeO-DMT, and it matters for understanding why some people work with both.
What 5-MeO-DMT Produces
5-MeO-DMT acts primarily through the 5-HT1A serotonin receptor. Its active duration is 20–45 minutes. What happens in those minutes is qualitatively unlike anything in the ibogaine experience: complete loss of the boundary between self and not-self, no narrative content, often no ability to locate where the body is.
Research documented in multiple peer-reviewed contexts has found significant reductions in depression and anxiety ratings following single 5-MeO-DMT sessions, with effects persisting at four-week follow-up. The mechanism appears to involve temporary dissolution of the chronic maintenance of a separate self — and what that temporary dissolution produces in lasting terms depends substantially on what the person does in the integration weeks that follow.
5-MeO-DMT is not a lighter version of ibogaine. It is shorter, not easier. The intensity of ego dissolution in 20–45 minutes produces its own demands, and the absence of narrative content makes integration harder, not simpler — because there is nothing to put into words, and the tools people normally use to process experience do not apply to an experience in which there was no one present to have it.
Why Some People Work with Both
The pattern is consistent among the people who come having already worked with ibogaine elsewhere: the ceremony was profound. They left with clarity, reduced craving, and what felt like the beginning of something different. Six weeks later, they were back where they started — or close to it — because the self that now understood these things was still holding them in the same way. The content had shifted. The structure holding it had not.
This is one rationale for 5-MeO-DMT following ibogaine. Ibogaine works on the specific content of a person's history — the particular events, the autobiography. 5-MeO-DMT works on the structure below the content: the sense of a separate self that has been organising that autobiography and maintaining the conditions for suffering. For some people, encountering the content first and then releasing the grip of the self holding it produces a more complete resolution than either medicine would alone.
The reverse situation also exists. Some people have worked with 5-MeO-DMT alone and returned with a profound experience they cannot contextualise. The dissolution was real — but they came back without a framework for understanding what had shifted or why. In those cases, ibogaine's biographical, narrative quality can provide what 5-MeO-DMT did not: a specific, grounded encounter with the content that underlies what the dissolution temporarily addressed.
Neither sequence is universal. The question of whether both medicines are appropriate — and in what order — is determined during the intake process, based on the individual's specific situation and what has already been attempted.
The Sequencing Question: Which Medicine Comes First
When both medicines are used, ibogaine typically comes first. The reasoning is both pharmacological and experiential: the ibogaine ceremony is longer and more physically demanding — 12–24 hours of active engagement. The ego dissolution of 5-MeO-DMT is easier to navigate if the person has already done significant biographical work. The content ibogaine surfaces is less likely to destabilise when the self that had been holding it later dissolves.
The reverse — 5-MeO-DMT followed by ibogaine — is less common but not categorically wrong. It requires a specific rationale based on what the individual has already attempted and what the intake conversation reveals. What governs the sequencing decision is not a protocol but a question: what does this person actually need, and in what order?
The two medicines are never administered in the same session. The ibogaine ceremony concludes, a 2–3 day recovery period follows, and the 5-MeO-DMT ceremony — if appropriate — takes place after that recovery, when the person is ready to engage with a second medicine rather than still processing the first.
What a Combined Programme Looks Like
At Transcend in Vancouver, a combined ibogaine and 5-MeO-DMT programme typically spans 5–7 days on-site. The ibogaine ceremony (12–24 hours active) takes place first, followed by 2–3 days of supported recovery. The 5-MeO-DMT ceremony (20–45 minutes active) follows if the intake process identified it as appropriate for the individual. Full ceremony details — including what medical oversight looks like throughout — are covered on the ceremony page.
Iboga ceremony costs $2,000–$5,000 CAD. This includes an on-site medical professional throughout the active hours, continuous cardiac monitoring, the medicine, and facilitation. Medical screening — 12-lead EKG, full blood panel, medication review, psychiatric history assessment — is conducted before any ceremony date is confirmed. 5-MeO-DMT ceremony costs $600–$1,500 CAD and includes full facilitation.
Integration coaching, available separately at $150–$300 CAD per session, can begin during the on-site recovery period and continue throughout the 4–6 weeks that follow. The integration page covers what that period requires and what working with a coach during the neuroplasticity window actually involves.
Vancouver is approximately 45 minutes from the US border — a practical consideration for Americans who cannot access either medicine domestically. Ibogaine is Schedule I in the United States. 5-MeO-DMT is similarly restricted in multiple US states and at the federal level. Neither medicine is listed under Canada's Controlled Drugs and Substances Act.
Who This Is Not For
The contraindications for a combined programme are the union of both medicines' contraindications — not a compromise between them. Every ibogaine contraindication applies. Every 5-MeO-DMT contraindication applies.
Absolute contraindications for ibogaine: QT prolongation, significant cardiac arrhythmia, or recent myocardial infarction; current SSRIs or SNRIs without a completed supervised taper — the risk of serotonin syndrome is real and potentially fatal, and there are no exceptions to this; methadone without a specific supervised transition protocol; lithium and most antipsychotics; severe liver or kidney disease; active psychosis or schizophrenia spectrum disorder; pregnancy.
Additional contraindications for 5-MeO-DMT: lithium is an absolute — the risk of seizure and cardiac events is not theoretical; personal or first-degree family history of schizophrenia or psychotic spectrum disorder; MAOIs. The SSRI and SNRI contraindication that applies to ibogaine applies equally to 5-MeO-DMT.
Someone in acute psychiatric crisis is not an appropriate candidate for either medicine. The experience amplifies what is present. Entering either medicine in a state of acute instability does not produce stability.
And someone seeking a shortcut to insight or a powerful experience to describe will consistently encounter something else. Both medicines tend to deliver what is needed, not what was hoped for. People who arrive seeking an experience rather than willing to encounter what the medicine shows them are not yet ready for this work — and the work tends to identify them clearly.
The full list of screening criteria is covered in the ibogaine contraindications post. The FAQ addresses the most common questions about candidacy and what the screening process involves.
Is This Right for You?
The relevant question is not whether the case for combining ibogaine and 5-MeO-DMT is compelling. It is whether you are at a point where conventional approaches have been thoroughly tried and found insufficient, whether you have the time and stability to move through a 5–7 day on-site programme, and whether you have adequate support arranged for the integration weeks that follow.
If you want to discuss whether a combined programme is appropriate for your specific situation, the application form is where that conversation begins. Every application receives a personal response within 2–3 business days. If medical screening indicates that one or both medicines are contraindicated for you, we will say so directly — at the screening stage, before any ceremony date is set.